Allergan acquires Vitae Pharma and with it VTP 43742 and VTP 38543.

Allergan plc , a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc. a clinical-stage biotechnology company, announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The Boards of Directors of both companies have unanimously approved the transaction. The acquisition will strengthen Allergan's dermatology product pipeline, with the addition of VTP-43742, a Phase II first-in-class, orally active ROR?t (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders. The acquisition also adds VTP-38543, a topical LXRbeta (Liver X Receptor beta) selective agonist for the potential treatment of atopic dermatitis. It is believed that VTP-38543 works by decreasing inflammation in damaged skin tissue and repairing the damaged outer layer of skin. VTP-38543 is currently in a Phase IIa proof-of-concept clinical trial .